Genpharmasec Ltd

Genpharmasec Annual Report

Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.

Genpharmasec Management Change

Genpharmasec Limited has re-appointed Sohan Chaturvedi as Executive Director for a 36-month term effective April 26, 2027. This change is approved by the Board.

Genpharmasec Annual General Meeting

Genpharmasec Limited has announced the closure of its share transfer books from September 23 to 29, 2026, for the 34th Annual General Meeting.

Genpharmasec Board Meeting Outcome

Genpharmasec Limited announced the schedule for its 34th Annual General Meeting and approved the re-appointment of Mr. Sohan Chaturvedi as Whole Time Director.

Genpharmasec Promoter Buying: ₹0.71 Cr

Promoter and Director Rajesh Sadhwani acquired 65,00,000 equity shares via market purchase. This increases his stake from 14.09% to 15.26% in Genpharmasec Ltd.

Value

₹0.71 Cr

Promoter stake change

+1.17%

Genpharmasec Q1 FY27 Results: Net Loss of ₹0.2 Cr

Genpharmasec Ltd reported revenue from operations of ₹49.7 Cr (+314.2% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.

Key figure

Net loss ₹0.2 Cr

Genpharmasec Q4 FY26 Results: Turns Profitable, Net Profit ₹1.4 Cr

Genpharmasec Ltd reported revenue from operations of ₹55.4 Cr (+295.7% YoY) and net profit of ₹1.4 Cr for Q4 FY26.

Key figure

Net profit ₹1.4 Cr